23.20

2.43% 0.55

Pre-market: 24.00 0.80 +3.45%

Pacira Biosciences Inc (PCRX)

Overview News Price History Option Chain Financials Discussions Forecast

Pacira Biosciences Inc stock is traded at $23.20, with a volume of 751.46K. It is up +2.43% in the last 24 hours and down -0.90% over the past month. Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

Previous Close:

$22.65

Open:

$22.57

24h Volume:

751.46K

Relative Volume:

0.83

Market Cap:

$939.37M

Revenue:

$726.41M

Net Income/Loss:

$7.03M

P/E Ratio:

147.68

EPS:

0.1571

Net Cash Flow:

$136.66M

1W Performance:

+5.74%

1M Performance:

-0.90%

6M Performance:

-10.94%

1Y Performance:

-6.60%

1-Day Range:

$22.30

$23.21

1-Week Range:

$21.16

$23.21

52-Week Range:

$18.80

$27.98

Pacira Biosciences Inc Stock (PCRX) Company Profile

Name

Pacira Biosciences Inc

Sector

Healthcare (1113)

Industry

Drug Manufacturers - Specialty & Generic (84)

Phone

650-242-8052

Address

2000 SIERRA POINT PARKWAY, BRISBANE, NJ

Employee

829

Twitter

Next Earnings Date

2024-11-06

Latest SEC Filings

PCRX's Discussions on Twitter

Compare PCRX vs TAK, ZTS, HLN, TEVA, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PCRX Pacira Biosciences Inc	23.20	939.37M	726.41M	7.03M	136.66M	0.1571
TAK Takeda Pharmaceutical Co Adr	18.04	56.99B	29.85B	776.90M	4.35B	0.2408
ZTS Zoetis Inc	115.93	48.94B	9.47B	2.67B	2.28B	6.0218
HLN Haleon Plc Adr	9.70	43.30B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	29.14	33.94B	17.41B	1.43B	1.00B	1.2182
UTHR United Therapeutics Corp	531.82	23.31B	3.18B	1.33B	1.04B	27.90

Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-09-25	Initiated	Barclays	Equal Weight
Nov-17-25	Initiated	H.C. Wainwright	Buy
Jul-25-25	Upgrade	Truist	Hold → Buy
Jan-30-25	Upgrade	Truist	Sell → Hold
Aug-13-24	Downgrade	Truist	Buy → Sell
Aug-12-24	Downgrade	JP Morgan	Overweight → Underweight
Aug-12-24	Downgrade	Piper Sandler	Overweight → Neutral
Aug-12-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Aug-12-24	Downgrade	Raymond James	Outperform → Mkt Perform
Jul-03-24	Downgrade	Barclays	Overweight → Equal Weight
Mar-07-24	Resumed	JP Morgan	Overweight
Dec-20-23	Initiated	Raymond James	Outperform
Aug-03-23	Upgrade	TD Cowen	Market Perform → Outperform
Jan-31-23	Resumed	Wedbush	Outperform
Oct-21-22	Resumed	Jefferies	Buy
Jan-03-22	Resumed	JP Morgan	Overweight
Jul-26-21	Upgrade	JP Morgan	Neutral → Overweight
Apr-21-21	Resumed	JP Morgan	Neutral
Apr-09-21	Initiated	Berenberg	Buy
Apr-07-21	Resumed	RBC Capital Mkts	Outperform
Feb-11-21	Downgrade	Northland Capital	Outperform → Market Perform
Jan-21-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
Sep-21-20	Upgrade	Northland Capital	Market Perform → Outperform
Jul-06-20	Reiterated	Needham	Buy
May-27-20	Initiated	Guggenheim	Neutral
Apr-07-20	Initiated	Northland Capital	Outperform
Mar-20-20	Upgrade	SVB Leerink	Mkt Perform → Outperform
Feb-24-20	Reiterated	H.C. Wainwright	Buy
Jan-24-20	Initiated	SunTrust	Buy
Jan-23-20	Initiated	SunTrust	Buy
Nov-06-19	Initiated	BTIG Research	Buy
Jun-11-19	Initiated	Barclays	Overweight
May-06-19	Upgrade	Mizuho	Underperform → Neutral
May-02-19	Upgrade	Stifel	Sell → Hold
Feb-01-19	Downgrade	Mizuho	Neutral → Underperform
Aug-06-18	Downgrade	BofA/Merrill	Buy → Neutral
Apr-09-18	Reiterated	H.C. Wainwright	Buy
Mar-21-18	Reiterated	Mizuho	Neutral
Feb-16-18	Downgrade	Needham	Buy → Hold
Jan-19-18	Initiated	Seaport Global Securities	Buy
Jan-04-18	Reiterated	Canaccord Genuity	Buy
Jan-03-18	Initiated	Leerink Partners	Mkt Perform

View All

Pacira Biosciences Inc Stock (PCRX) Latest News

Mar 21, 2026

Pacira faces board fight as activist investor criticizes CEO pay, missed earnings - MSN

Mar 21, 2026

Mar 20, 2026

(PCRX) Movement as an Input in Quant Signal Sets - Stock Traders Daily

Mar 20, 2026

Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat

Mar 20, 2026

Mar 19, 2026

Insider Sell: Jonathan Slonin Sells Shares of Pacira BioSciences Inc (PCRX) - GuruFocus

Mar 19, 2026

Froimson Mark sells Pacira BioSciences (PCRX) shares for $10905 By Investing.com - Investing.com South Africa

Mar 19, 2026

Insider Selling: Pacira BioSciences (NASDAQ:PCRX) Insider Sells 3,261 Shares of Stock - MarketBeat

Mar 19, 2026

Froimson Mark sells Pacira BioSciences (PCRX) shares for $10905 - Investing.com UK

Mar 19, 2026

Pacira BioSciences’ chief medical officer sells $74k in stock By Investing.com - Investing.com Canada

Mar 19, 2026

Pacira BioSciences (PCRX) director receives 6,163 restricted stock units in equity grant - Stock Titan

Mar 19, 2026

Pacira BioSciences (NASDAQ: PCRX) CMO sells 3,261 company shares - Stock Titan

Mar 19, 2026

Pacira BioSciences (PCRX) director sells 500 common shares in open market - Stock Titan

Mar 19, 2026

Mar 18, 2026

Pacira BioSciences unveils support hub for caregivers addressing chronic pain - Traders Union

Mar 18, 2026

Form 144 Pacira BioSciences For: 17 March By Investing.com - Investing.com Australia

Mar 18, 2026

Mar 17, 2026

Profit Review: Will Pacira BioSciences Inc benefit from seasonality2026 Big Picture & Weekly High Return Stock Opportunities - baoquankhu1.vn

Mar 14, 2026

Radcliffe Capital Management L.P. Takes $1.23 Million Position in Pacira BioSciences, Inc. $PCRX - MarketBeat

Mar 14, 2026

Mar 13, 2026

Pacira BioSciences advances non opioid pain therapies to transform patient care - Traders Union

Mar 13, 2026

Pacira BioSciences Reaffirms Commitment to Shareholder Value Creation - Sahm

Mar 13, 2026

Mar 12, 2026

Activist DOMA takes 7.3% Pacira (NASDAQ: PCRX) stake and targets CEO, board - Stock Titan

Mar 12, 2026

Pacira BioSciences responds to DOMA director nominations - Investing.com Australia

Mar 12, 2026

DOMA Perpetual Nominates Three Highly Qualified Candidates for the Board of Pacira BioSciences, Inc. - Morningstar

Mar 12, 2026

[DFAN14A] Pacira BioSciences, Inc. SEC Filing - Stock Titan

Mar 12, 2026

Activist hedge fund pushes Pacira BioSciences to sell itself - The Business Journals

Mar 12, 2026

Pacira Faces Board Fight As Activist Investor Criticizes CEO Pay, Missed Earnings - Benzinga

Mar 12, 2026

Pacira BioSciences responds to DOMA director nominations By Investing.com - Investing.com India

Mar 12, 2026

Mar 11, 2026

DOMA nominates three for Pacira Biosciences (NASDAQ: PCRX), holds 7.1% - Stock Titan

Mar 11, 2026

Pacira BioSciences shares rise 2% as activist pushes for CEO removal - Investing.com Canada

Mar 11, 2026

Pacira BioSciences (NASDAQ:PCRX) Downgraded to "Strong Sell" Rating by Zacks Research - MarketBeat

Mar 11, 2026

Mar 09, 2026

Liquidity Mapping Around (PCRX) Price Events - Stock Traders Daily

Mar 09, 2026

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRX) And Encourages Shareholders to Reach Out - ACCESS Newswire

Mar 09, 2026

Mar 08, 2026